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Th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
2017/18
provides
con
cise
overview
s
of
th
e
key
properties
of
n
early
1800
h
um
an
drug
targets
w
ith
an
em
ph
asis
on
selective
ph
arm
acology
(w
h
ere
available),
plus
lin
ks
to
an
open
access
kn
ow
ledgebase
of
drug
targets
an
d
th
eir
ligan
ds
(w
w
w
.guidetoph
arm
acology.org),w
h
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provides
m
ore
detailed
view
s
of
target
an
d
ligan
d
properties.
A
lth
ough
th
e
C
on
cise
G
uide
represen
ts
approxim
ately
400
pages,th
e
m
aterial
presen
ted
is
substan
tially
reduced
com
pared
to
in
form
ation
an
d
lin
ks
presen
ted
on
th
e
w
ebsite.
It
provides
a
perm
an
en
t,citable,poin
t-in
-tim
e
record
th
at
w
ill
survive
database
updates.
Th
e
full
con
ten
ts
of
th
is
section
can
be
foun
d
at
h
ttp://on
lin
elibrary.w
iley.com
/doi/10.1111/bph
.13880/full.
N
uclear
h
orm
on
e
receptors
are
on
e
of
th
e
eigh
t
m
ajor
ph
arm
acologicaltargets
in
to
w
h
ich
th
e
G
uide
is
divided,w
ith
th
e
oth
ers
bein
g:
G
protein
-coupled
receptors,ligan
d-gated
ion
ch
an
n
els,voltage-gated
ion
ch
an
n
els,oth
er
ion
ch
an
n
els,catalytic
receptors,en
zym
es
an
d
tran
sporters.Th
ese
are
presen
ted
w
ith
n
om
en
clature
guidan
ce
an
d
sum
m
ary
in
form
ation
on
th
e
best
available
ph
arm
acologicaltools,alon
gside
key
referen
ces
an
d
suggestion
s
for
furth
er
readin
g.Th
e
lan
dscape
form
at
ofth
e
C
on
cise
G
uide
is
design
ed
to
facilitate
com
parison
ofrelated
targets
from
m
aterialcon
tem
porary
to
m
id-2017,an
d
supersedes
data
presen
ted
in
th
e
2015/16
an
d
2013/14
C
on
cise
G
uides
an
d
previous
G
uides
to
R
eceptors
an
d
C
h
an
n
els.
It
is
produced
in
close
con
jun
ction
w
ith
th
e
N
om
en
clature
C
om
m
ittee
of
th
e
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology
(N
C
-IU
PH
A
R
),th
erefore,providin
g
officialIU
PH
A
R
classification
an
d
n
om
en
clature
for
h
um
an
drug
targets,w
h
ere
appropriate.
C
o
n
fl
ict
o
f
in
terest
Th
e
auth
ors
state
th
at
th
ere
are
n
o
con
flicts
of
in
terest
to
declare.
©
2017
Th
e
A
uth
ors.British
Journ
alof
Ph
arm
acology
publish
ed
by
Joh
n
W
iley
&
Son
s
Ltd
on
beh
alf
of
British
Ph
arm
acologicalSociety.
Th
is
is
an
open
access
article
un
der
th
e
term
s
ofth
e
C
reative
C
om
m
on
s
A
ttribution
Licen
se,w
h
ich
perm
its
use,distribution
an
d
reproduction
in
an
y
m
edium
,provided
th
e
origin
alw
ork
is
properly
cited.
O
verview
:
N
uclear
receptors
are
specialised
tran
scription
fac-
tors
w
ith
com
m
on
alities
of
sequen
ce
an
d
structure,
w
h
ich
bin
d
ash
om
o-orh
eterodim
ersto
specific
con
sen
sussequen
cesofD
N
A
(respon
se
elem
en
ts)
in
th
e
prom
oter
region
of
particular
target
gen
es.
Th
ey
regulate
(eith
er
prom
otin
g
or
repressin
g)
tran
scrip-
tion
of
th
ese
target
gen
es
in
respon
se
to
a
variety
of
en
dogen
ous
ligan
ds.
En
dogen
ous
agon
ists
are
h
ydroph
obic
en
tities
w
h
ich
,
w
h
en
boun
d
to
th
e
receptor
prom
ote
con
form
ation
al
ch
an
ges
in
th
e
receptor
to
allow
recruitm
en
t
(or
dissociation
)
of
protein
partn
ers,gen
eratin
g
a
large
m
ultiprotein
com
plex.
Tw
o
m
ajorsubclassesofn
uclearreceptorsw
ith
iden
tified
en
doge-
n
ous
agon
ists
can
be
iden
tified:
steroid
an
d
n
on
-steroid
h
or-
m
on
e
receptors.
Steroid
h
orm
on
e
receptors
fun
ction
typically
as
dim
eric
en
tities
an
d
are
th
ough
t
to
be
residen
t
outside
th
e
n
ucleus
in
th
e
un
ligan
ded
state
in
a
com
plex
w
ith
ch
aperon
e
protein
s,
w
h
ich
are
liberated
upon
agon
ist
bin
din
g.
M
igration
to
th
e
n
ucleus
an
d
in
teraction
w
ith
oth
er
regulators
of
gen
e
tran
scription
,in
cludin
g
R
N
A
polym
erase,acetyltran
sferases
an
d
deacetylases,
allow
s
gen
e
tran
scription
to
be
regulated.
N
on
-
steroid
h
orm
on
e
receptors
typically
exh
ibita
greater
distribution
in
th
e
n
ucleus
in
th
e
un
ligan
ded
state
an
d
in
teract
w
ith
oth
er
n
uclear
receptors
to
form
h
eterodim
ers,as
w
ellas
w
ith
oth
er
reg-
ulators
of
gen
e
tran
scription
,
leadin
g
to
ch
an
ges
in
gen
e
tran
-
scription
upon
agon
ist
bin
din
g.
Selectivity
of
gen
e
regulation
is
brough
t
about
th
rough
in
terac-
tion
of
n
uclear
receptors
w
ith
particular
con
sen
sus
sequen
ces
of
D
N
A
,
w
h
ich
are
arran
ged
typically
as
repeats
or
in
verted
palin
-
drom
es
to
allow
accum
ulation
of
m
ultiple
tran
scription
factors
in
th
e
prom
oter
region
s
of
gen
es.
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horm
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receptors
N
uclear
h
orm
on
e
receptors→
1A
.Th
yroid
h
orm
on
e
receptors
O
verview
:
Th
yroid
h
orm
on
e
receptors
(T
R
s,
n
o
m
en
cla-
tu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[41])
are
n
uclear
h
orm
on
e
receptors
of
th
e
N
R
1A
fam
ily,
w
ith
diverse
roles
regulatin
g
m
acron
utrien
t
m
etabolism
,cogn
ition
an
d
cardiovascular
h
om
e-
ostasis.TR
s
are
activated
by
th
yroxin
e
(T
4 )an
d
th
yroid
h
orm
on
e
(triiodoth
yron
in
e).
O
n
ce
activated
by
a
ligan
d,th
e
receptor
acts
as
a
tran
scription
factor
eith
er
as
a
m
on
om
er,h
om
odim
er
orh
et-
erodim
er
w
ith
m
em
bers
of
th
e
retin
oid
X
receptor
fam
ily.
N
H
-3
h
asbeen
described
asan
an
tagon
istatTR
sw
ith
m
odestselectivity
for
TRβ
[110].
N
om
enclature
Thyroid
horm
one
receptor-α
Thyroid
horm
one
receptor-β
System
atic
nom
enclature
N
R1A1
N
R1A2
H
G
N
C
,U
niProt
TH
RA,P10827
TH
RB,P10828
Rank
order
ofpotency
triiodothyronine
>
T
4
triiodothyronine
>
T
4
Agonists
dextrothyroxine
[19]
dextrothyroxine
[19]
Selective
agonists
–
sobetirom
e
[26,130]
C
o
m
m
en
ts:
A
n
in
teraction
w
ith
in
tegrin
α
V
β3
h
as
been
suggested
to
un
derlie
plasm
a
m
em
bran
e
localization
of
TR
s
an
d
n
on
-gen
om
ic
sign
allin
g
[8].O
n
e
splice
varian
t,TRα
2 ,lacks
a
fun
ction
al
D
N
A
-
bin
din
g
dom
ain
an
d
appears
to
act
as
a
tran
scription
suppressor.
A
lth
ough
radioligan
d
bin
din
g
assays
h
ave
been
described
for
th
ese
receptors,th
e
radioligan
ds
are
n
ot
com
m
ercially
available.
Fu
rth
er
read
in
g
o
n
1A
.T
h
yro
id
h
o
rm
o
n
e
recep
to
rs
D
avis
PJ
et
al.
(2016)
N
on
gen
om
ic
action
s
of
th
yroid
h
orm
on
e.
N
at
Rev
Endocrinol
12
:
111-21
[PM
ID
:26668118]
Elbers
LP
etal.(2016)Th
yroid
H
orm
on
e
M
im
etics:th
e
Past,C
urren
tStatus
an
d
Future
C
h
allen
ges.
C
urr
A
theroscler
Rep
18
:14
[PM
ID
:26886134]
Flam
an
t
F
et
al.
(2006)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
LIX
.Th
e
ph
arm
acology
an
d
classi-
fication
of
th
e
n
uclear
receptor
superfam
ily:
th
yroid
h
orm
on
e
receptors.
Pharm
acol.
Rev.
58
:
705-11
[PM
ID
:17132849]
M
en
doza
A
et
al.
(2017)
N
ew
in
sigh
ts
in
to
th
yroid
h
orm
on
e
action
.
Pharm
acolT
her173
:
135-145
[PM
ID
:28174093]
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1B.Retinoic
acid
receptors
N
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h
orm
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etin
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acid
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etin
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receptors
(n
o
m
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clatu
re
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b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[46])
are
n
uclear
h
orm
on
e
receptors
of
th
e
N
R
1B
fam
ily
activated
by
th
e
vitam
in
A
-derived
agon
ists
tretin
oin
(A
TR
A
)
an
d
alitretin
oin
,an
d
th
e
R
A
R
-selective
syn
th
etic
agon
ists
TTN
PB
an
d
adapalen
e.BM
S493
is
a
fam
ily-selective
an
tagon
ist
[47].
N
om
enclature
Retinoic
acid
receptor-α
Retinoic
acid
receptor-β
Retinoic
acid
receptor-γ
System
atic
nom
enclature
N
R1B1
N
R1B2
N
R1B3
H
G
N
C
,U
niProt
RARA,P10276
RARB,P10826
RARG
,P13631
Agonists
tretinoin
[25]
tretinoin
[25]
tretinoin
[25]
Sub/fam
ily-selective
agonists
tazarotene
[25]
tazarotene
[25],adapalene
[24]
tazarotene
[25],adapalene
[24]
Selective
agonists
BM
S753
[53],tam
ibarotene
[146],Ro
40-6055
[33]
AC
261066
[89],AC
55649
[88,89]
AH
PN
[24]
Selective
antagonists
Ro
41-5253
(pIC
50
6.3–7.2)
[2,69]
–
M
M
11253
[76]
C
o
m
m
en
ts:R
o
41-5253
h
as
been
suggested
to
be
a
PPA
Rγ
agon
ist
[129].LE135
is
an
an
tagon
ist
w
ith
selectivity
for
R
A
Rα
an
d
R
A
Rβ
com
pared
w
ith
R
A
Rγ
[84].
Fu
rth
er
read
in
g
o
n
1B
.R
etin
o
ic
acid
recep
to
rs
D
uon
g
V
etal.(2011)
Th
e
m
olecular
ph
ysiology
ofn
uclear
retin
oic
acid
receptors.From
h
ealth
to
disease.
Biochim
.Biophys.A
cta
1812
:1023-31
[PM
ID
:20970498]
G
erm
ain
P
et
al.
(2006)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
LX
.R
etin
oic
acid
receptors.
Phar-
m
acol.Rev.58
:712-25
[PM
ID
:17132850]
Laran
ge
A
etal.(2016)
R
etin
oic
A
cid
an
d
R
etin
oic
A
cid
R
eceptors
as
Pleiotropic
M
odulators
of
th
e
Im
m
un
e
System
.
A
nnu
Rev
Im
m
unol34
:369-94
[PM
ID
:27168242]
Saeed
A
et
al.
(2017)
Th
e
in
terrelation
sh
ip
betw
een
bile
acid
an
d
vitam
in
A
h
om
eostasis.
Biochim
Biophys
A
cta
1862
:496-512
[PM
ID
:28111285]
1C
.Peroxisom
e
proliferator-activated
receptors
N
uclear
h
orm
on
e
receptors→
1C
.Peroxisom
e
proliferator-activated
receptors
O
verview
:Peroxisom
e
proliferator-activated
receptors
(P
PA
R
s,
n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
-
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[101])
are
n
uclear
h
orm
on
e
receptors
of
th
e
N
R
1C
fam
ily,
w
ith
diverse
roles
reg-
ulatin
g
lipid
h
om
eostasis,
cellular
differen
tiation
,
proliferation
an
d
th
e
im
m
un
e
respon
se.
PPA
R
s
h
ave
m
an
y
poten
tial
en
doge-
n
ous
agon
ists
[13,101],in
cludin
g
15-deoxy-!
12,14-PG
J2 ,prosta-
cyclin
(PG
I2 ),
m
an
y
fatty
acids
an
d
th
eir
oxidation
products,
lysoph
osph
atidic
acid
(LPA
)
[98],
13-H
O
D
E,
15S-H
ETE,
Paz-PC
,
azelaoyl-PA
F
an
d
leukotrien
e
B4
(LTB
4 ).
Bezafibrate
acts
as
a
n
on
-selective
agon
ist
for
th
e
PPA
R
fam
ily
[155].
Th
ese
recep-
tors
also
bin
d
h
ypolipidaem
ic
drugs
(PPA
Rα
)
an
d
an
ti-diabetic
th
iazolidin
edion
es
(PPA
Rγ),
as
w
ell
as
m
an
y
n
on
-steroidal
an
ti-
in
flam
m
atory
drugs,
such
as
sulin
dac
an
d
in
dom
eth
acin
.
O
n
ce
activated
by
a
ligan
d,
th
e
receptor
form
s
a
h
eterodim
er
w
ith
m
em
bers
of
th
e
retin
oid
X
receptor
fam
ily
an
d
can
act
as
a
tran
-
scription
factor.
A
lth
ough
radioligan
d
bin
din
g
assays
h
ave
been
described
for
all
th
ree
receptors,
th
e
radioligan
ds
are
n
ot
com
-
m
ercially
available.
C
om
m
on
ly,
receptor
occupan
cy
studies
are
con
ducted
usin
g
fluorescen
t
ligan
ds
an
d
trun
cated
form
s
of
th
e
receptor
lim
ited
to
th
e
ligan
d
bin
din
g
dom
ain
.
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N
om
enclature
Peroxisom
e
proliferator-activated
receptor-α
Peroxisom
e
proliferator-activated
receptor-β/δ
Peroxisom
e
proliferator-activated
receptor-γ
System
atic
nom
enclature
N
R1C
1
N
R1C
2
N
R1C
3
H
G
N
C
,U
niProt
PPARA,Q
07869
PPARD
,Q
03181
PPARG
,P37231
Selective
agonists
G
W
7647
[17,18],C
P-775146
[67],
pirinixic
acid
[155],gem
fibrozil[31]
G
W
0742X
[50,148],G
W
501516
[112]
G
W
1929
[17],bardoxolone
(Partialagonist)
[149],
rosiglitazone
[59,80,86,161],troglitazone
[59,161],
pioglitazone
[7,59,127,161],ciglitazone
[59]
Selective
antagonists
G
W
6471
(pIC
50
6.6)
[158]
G
SK0660
(pIC
50
6.5)
[131]
T0070907
(pK
i 9)
[77],G
W
9662
(Irreversible
inhibition)
(pIC
50
8.1)
[78],C
D
D
O
-M
e
(pK
i 6.9)
[149]
C
o
m
m
en
ts:A
s
w
ith
th
e
estrogen
receptor
an
tagon
ists,m
an
y
agen
ts
sh
ow
tissue-selective
efficacy
(e.g.[12,109,124]).A
gon
ists
w
ith
m
ixed
activity
at
PPA
Rα
an
d
PPA
Rγ
h
ave
also
been
described
(e.g
[35,
52,159]).
Fu
rth
er
read
in
g
o
n
1C
.P
ero
x
iso
m
e
p
ro
liferato
r-activated
recep
to
rs
C
h
ean
g
W
S
etal.(2015)Th
e
peroxisom
e
proliferator-activated
receptors
in
cardiovasculardiseases:
experim
en
talben
efits
an
d
clin
icalch
allen
ges.Br
JPharm
acol172
:5512-22
[PM
ID
:25438608]
G
ross
B
etal.(2017)PPA
R
s
in
obesity-in
duced
T2D
M
,dyslipidaem
ia
an
d
N
A
FLD
.N
atRev
Endocrinol
13
:36-49
[PM
ID
:27636730]
H
allen
borg
P
etal.(2016)Th
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proliferator-
activated
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orm
on
e
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1D
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ev-Erb
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O
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R
ev-erb
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[6])
h
ave
yet
to
be
officially
paired
w
ith
an
en
dogen
ous
ligan
d,
but
are
th
ough
t
to
be
activated
by
h
em
e.
N
om
enclature
Rev-Erb-α
Rev-Erb-β
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atic
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enclature
N
R1D
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N
R1D
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H
G
N
C
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N
R1D
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N
R1D
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hem
e
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1F.Retinoic
acid-related
orphans
N
uclear
h
orm
on
e
receptors→
1F.R
etin
oic
acid-related
orph
an
s
O
verview
:
R
etin
oic
acid
receptor-related
orph
an
receptors
(R
O
R
,n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[6])
h
ave
yet
to
be
assign
ed
a
defin
itive
en
dogen
ous
ligan
d,alth
ough
R
O
Rα
m
ay
be
syn
th
esized
w
ith
a
‘captured’agon
ist
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as
ch
olesterol[65,66].
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om
enclature
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orphan
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RAR-related
orphan
receptor-β
RAR-related
orphan
receptor-γ
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enclature
N
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N
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N
R1F3
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N
C
,U
niProt
RO
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o
m
m
en
ts:tretin
oin
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ow
s
selectivity
for
R
O
Rβ
w
ith
in
th
e
R
O
R
fam
ily
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O
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h
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to
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n
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m
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1H
.Liver
X
receptor-like
receptors
N
uclear
h
orm
on
e
receptors→
1H
.Liver
X
receptor-like
receptors
O
verview
:
Liver
X
an
d
farn
esoid
X
receptors
(LX
R
an
d
FX
R
,n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[105])
are
m
em
bers
of
a
steroid
an
alogue-activated
n
uclear
receptor
subfam
ily,w
h
ich
form
h
eterodim
ers
w
ith
m
em
bers
of
th
e
retin
oid
X
receptor
fam
ily.
En
dogen
ous
ligan
ds
for
LX
Rs
in
clude
h
ydroxych
olesterols
(O
H
C
),w
h
ile
FX
R
s
appear
to
be
activated
by
bile
acids.
N
om
enclature
Farnesoid
X
receptor
Farnesoid
X
receptor-β
Liver
X
receptor-α
Liver
X
receptor-β
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enclature
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R1H
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R1H
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R1H
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G
N
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N
R1H
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R1H
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R1H
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N
R1H
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Potency
order
chenodeoxycholic
acid
>
lithocholic
acid,
deoxycholic
acid
[92,115]
–
20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol>
25-hydroxycholesterol,
27-hydroxycholesterol[79]
20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol>
25-hydroxycholesterol,
27-hydroxycholesterol[79]
Endogenous
agonists
–
lanosterol[113]–
M
ouse
–
–
Selective
agonists
G
W
4064
[94],obeticholic
acid
[116],
fexaram
ine
[36]
–
–
–
Selective
antagonists
guggulsterone
(pIC
50
5.7–6)
[157]
–
–
–
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o
m
m
en
ts:T0901317
[122]an
d
G
W
3965
[27]are
syn
th
etic
agon
ists
actin
g
at
both
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Rα
an
d
LX
Rβ
w
ith
less
th
an
10-fold
selectivity.
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1I.V
itam
in
D
receptor-like
receptors
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uclear
h
orm
on
e
receptors→
1I.V
itam
in
D
receptor-like
receptors
O
verview
:
V
itam
in
D
(V
D
R
),Pregn
an
e
X
(PX
R
)
an
d
C
on
stitutive
A
n
drostan
e
(C
A
R
)
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[105])
are
m
em
bers
of
th
e
N
R
1I
fam
ily
of
n
uclear
receptors,w
h
ich
form
h
eterodim
ers
w
ith
m
em
bers
of
th
e
retin
oid
X
receptor
fam
ily.
PX
R
an
d
C
A
R
are
activated
by
a
ran
ge
of
exogen
ous
com
poun
ds,
w
ith
n
o
establish
ed
en
dogen
ous
ph
ysiologicalagon
ists,alth
ough
h
igh
con
cen
tration
s
of
bile
acids
an
d
bile
pigm
en
ts
activate
PX
R
an
d
C
A
R
[105].
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receptor
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receptor
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G
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agonists
1,25-dihydroxyvitam
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D
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17β-estradiol[64]
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Selective
agonists
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[106,152],5β-pregnane-3,20-dione
[64],lovastatin
[81],rifam
picin
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[144]–
M
ouse,C
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[91]
Selective
antagonists
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(pIC
50
8.2)
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ZK159222
(pIC
50
7.5)
[42,60]
–
–
C
om
m
ents
–
–
clotrim
azole
[107]and
T0901317
[68]although
acting
at
other
sites,function
as
antagonists
ofthe
constitutive
androstane
receptor.
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verview
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en
clature
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epatocyte
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uclear
factor-4
receptors
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by
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
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[6].W
h
ile
lin
oleic
acid
h
as
been
iden
tified
as
th
e
en
dogen
ous
ligan
d
for
H
N
F4α
its
fun
ction
rem
ain
s
am
biguous
[163].H
N
F4γ
h
as
yet
to
be
paired
w
ith
an
en
dogen
ous
ligan
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agonists
linoleic
acid
[163]
–
Selective
antagonists
BI6015
[71]
–
C
om
m
ents
H
N
F4α
has
constitutive
transactivation
activity
[163]and
binds
D
N
A
as
a
hom
odim
er
[63].
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2B.Retinoid
X
receptors
N
uclear
h
orm
on
e
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etin
oid
X
receptors
O
verview
:
R
etin
oid
X
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[45])
are
N
R
2B
fam
ily
m
em
bers
activated
by
alitretin
oin
an
d
th
e
R
X
R
-selective
agon
ists
bexaroten
e
an
d
LG
100268,som
etim
es
referred
to
as
rexin
oids.
U
V
I3003
[108]
an
d
H
X
531
[37]
h
ave
been
described
as
a
pan
-R
X
R
an
tagon
ists.
Th
ese
receptors
form
R
X
R
-R
A
R
h
eterodim
ers
an
d
R
X
R
-R
X
R
h
om
odim
ers
[22,96].
N
om
enclature
Retinoid
X
receptor-α
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X
receptor-β
Retinoid
X
receptor-γ
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atic
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enclature
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2C
.Testicular
receptors
N
uclear
h
orm
on
e
receptors→
2C
.Testicular
receptors
O
verview
:Testicular
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
u
clear
H
o
rm
o
n
e
R
ecep
to
rs
[6])
h
ave
yet
to
be
officially
paired
w
ith
an
en
dogen
ous
ligan
d,
alth
ough
testicular
receptor
4
h
as
been
reported
to
respon
d
to
retin
oids.
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om
enclature
Testicular
receptor
2
Testicular
receptor
4
System
atic
nom
enclature
N
R2C
1
N
R2C
2
H
G
N
C
,U
niProt
N
R2C1,P13056
N
R2C2,P49116
Endogenous
agonists
–
retinol[169],tretinoin
[169]
C
om
m
ents
Form
s
a
heterodim
er
w
ith
TR4;gene
disruption
appears
w
ithout
effect
on
testicular
developm
ent
or
function
[132].
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Estrogen
receptor-α
Estrogen
receptor-β
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propylpyrazoletriol[73,135],ethinylestradiol[62]
W
AY200070
[93],diarylpropionitrile
[100,135],prinaberel[29,93]
Sub/fam
ily-selective
antagonists
bazedoxifene
(pIC
50
7.6)
[103]
bazedoxifene
(pIC
50
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[103]
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iphene
(pK
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(pK
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(pK
i 6.9)
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-TH
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blocked
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oxifen
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[ 3H
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d
[ 3H
]tam
oxifen
.
M
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to
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receptors
appear
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tissue-specific
efficacy
(e.g.Tam
oxifen
is
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ist
at
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receptors
in
th
e
breast,but
is
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ist
at
estrogen
receptors
in
th
e
uterus),
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e
descriptor
SER
M
(selective
estrogen
receptor
m
odulator)
or
Sn
uR
M
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m
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Rank
order
ofpotency
dihydrotestosterone
[142]>
testosterone
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aldosterone,deoxycortisone
[125]
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testosterone
propionate
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esterone
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(pK
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(pIC
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(pIC
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(pIC
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[133],hydroxyflutam
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(pEC
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[148],galeterone
(pIC
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[56],flutam
ide
(pK
i 5.4)
[147]
onapristone
(pIC
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7.6)
[165],ZK112993
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[ 3H
]dihydrotestosterone
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N
R3C2,P08235
PG
R,P06401
Rank
order
ofpotency
corticosterone,cortisol,aldosterone
[58,125],progesterone
[125]
progesterone
[38]
Selective
agonists
–
m
edroxyprogesterone
(Affinity
at
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an
PR-A)
[166],O
RG
2058,levonorgestrel[9,128]
Selective
antagonists
finerenone
(pIC
50
7.7)
[20],eplerenone
(pK
i 6.9)
[5],onapristone
(pIC
50
6.3)
[165],RU
28318,ZK112993
ulipristalacetate
(pIC
50
9.7)
[123],m
ifepristone
(M
ixed)
(pK
i 9)
[167],onapristone
(pK
i
7.7)
[54],ZK112993
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[ 3H
]aldosterone
(Selective
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[ 3H
]O
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Agonist)
C
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[ 3H
]dexam
eth
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M
R
in
vitro.
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tagon
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been
suggested
to
subdivide
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Type
I
(e.g.
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apriston
e)
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d
Type
II
(e.g.
ZK
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groups.
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groups
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to
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distin
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th
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receptor,leadin
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